Post-Transplant Outcomes in High-Risk Compared With Non-High-Risk Multiple Myeloma: A CIBMTR Analysis
In conclusion, we show HRM patients achieve similar day 100 post-transplant responses compared with non-HRM patients, but these responses are not sustained. Post-transplant therapy appeared to improve the poor outcomes of HRM.
Biol Blood Marrow Transplant
In The News
American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting